葛兰、周蔚文最新动向来了，药明生物重回中欧医疗创新前十大重仓

每日经济新闻07-19

最新披露的基金二季报显示，中欧基金的葛兰、周蔚文都有一些调仓换股的动作。其中在葛兰管理的医药主题基金方面，比较明显的变化是药明生物又回到中欧医疗创新的前十大重仓股中，爱尔眼科退出了前十大重仓股。而周蔚文管理的中欧新蓝筹混合、中欧新趋势混合，二季度均更换了3只重仓股，其中三一重工、三花智控、温氏股份新进中欧新蓝筹混合的前十大重仓股，温氏股份、三花智控、中远海能新进中欧新趋势混合的前十大重仓股。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2452123497?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-07-19 11:35","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2452123497","market":"hk","top_or_hot":-1,"title":"葛兰、周蔚文最新动向来了，药明生物重回中欧医疗创新前十大重仓","media":"每日经济新闻","content":"<div>\n<p>最新披露的基金二季报显示，中欧基金的葛兰、周蔚文都有一些调仓换股的动作。其中在葛兰管理的医药主题基金方面，比较明显的变化是药明生物又回到中欧医疗创新的前十大重仓股中，爱尔眼科退出了前十大重仓股。而周蔚文管理的中欧新蓝筹混合、中欧新趋势混合，二季度均更换了3只重仓股，其中三一重工、三花智控、温氏股份新进中欧新蓝筹混合的前十大重仓股，温氏股份、三花智控、中远海能新进中欧新趋势混合的前十大重仓股。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719113519aefa6fbf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>葛兰、周蔚文最新动向来了，药明生物重回中欧医疗创新前十大重仓</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n葛兰、周蔚文最新动向来了，药明生物重回中欧医疗创新前十大重仓\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-19 11:35 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719113519aefa6fbf&s=b><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>最新披露的基金二季报显示，中欧基金的葛兰、周蔚文都有一些调仓换股的动作。其中在葛兰管理的医药主题基金方面，比较明显的变化是药明生物又回到中欧医疗创新的前十大重仓股中，爱尔眼科退出了前十大重仓股。而周蔚文管理的中欧新蓝筹混合、中欧新趋势混合，二季度均更换了3只重仓股，其中三一重工、三花智控、温氏股份新进中欧新蓝筹混合的前十大重仓股，温氏股份、三花智控、中远海能新进中欧新趋势混合的前十大重仓股。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719113519aefa6fbf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0456827905.SGD","symbol_name":"JPMorgan Funds - China A (acc) SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719113519aefa6fbf&s=b","article_id":"2452123497","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240719113519aefa6fbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2452123497","pubTimestamp":1721360102,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"而周蔚文管理的中欧新蓝筹混合、中欧新趋势混合，二季度均更换了3只重仓股，其中三一重工、三花智控、温氏股份新进中欧新蓝筹混合的前十大重仓股，温氏股份、三花智控、中远海能新进中欧新趋势混合的前十大重仓股。药明生物回到中欧医疗创新的前十大重仓股中欧基金葛兰目前管理的公募产品有3只，最新披露的二季报显示，中欧医疗健康混合的规模约为328亿元，相比于一季度末的369亿元，有所下降。周蔚文进一步表示。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","LU0572944931.SGD":"Janus Henderson Horizon China Opportunities A2 SGD","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","LU0516423091.SGD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (SGD) ACC","LU0348825331.USD":"ALLIANZ CHINA EQUITY \"A\" (USD) INC","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","LU0823426308.USD":"法巴中国股票基金","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","LU1794554557.SGD":"Allianz All China Equity AT Acc H2-SGD","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","SG9999002463.SGD":"LionGlobal China Growth SGD","02269":"药明生物","LU0051755006.USD":"摩根大通中国A (dist)","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","LU0456846285.SGD":"JPMorgan Funds - Greater China A (acc) SGD","LU0516423174.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (USD) ACC","LU0327786744.USD":"Janus Henderson Horizon China Opportunities A2 USD","LU1688375341.USD":"贝莱德中国灵活股票基金","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1521":"挪威政府全球养老基金持仓","BK1610":"ETF&股票定投概念","LU0181495838.USD":"施罗德新兴亚洲A Acc","LU0417516902.SGD":"Allianz China Equity Cl AT Acc SGD","LU0823426480.USD":"法巴中国股票经典Dis","LU0052750758.USD":"富兰克林中国基金A Acc","LU0043850808.USD":"HSBC GIF ASIA EX JAPAN EQUITY \"AD\" INC","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","LU0359201612.USD":"贝莱德中国基金A2","BK1141":"生命科学工具和服务","BK1576":"医药外包概念","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU0516422440.USD":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"A\" (USD) ACC","LU0359202008.SGD":"Blackrock China Fund A2 SGD-H","LU0039217434.USD":"HSBC GIF CHINESE EQUITY \"AD\" INC","LU0140636845.USD":"施罗德大中华区股票A Acc","LU0516422952.EUR":"FULLERTON LUX FUNDS - ASIA FOCUS EQUITIES \"I\" (EUR) ACC","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","BK1589":"北水核心资产","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU0708995583.HKD":"TEMPLETON CHINA \"A\" (HKD) ACC","LU0856984785.SGD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"ACH\" (SGDHDG) ACC","LU0348735423.USD":"ALLIANZ HONG KONG EQUITY \"A\" (USD) INC","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","SG9999002562.SGD":"LionGlobal Asia Pacific SGD","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU1720050803.USD":"安联全方位中国股票基金"},"translate_title":"The latest trends of Gulen and Zhou Weiwen are here, WuXi Biologics has returned to the top ten heavyweight positions in medical innovation in China and Europe","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"最新披露的基金二季报显示，中欧基金的葛兰、周蔚文都有一些调仓换股的动作。其中在葛兰管理的医药主题基金方面，比较明显的变化是药明生物又回到中欧医疗创新的前十大重仓股中，爱尔眼科退出了前十大重仓股。而周蔚文管理的中欧新蓝筹混合、中欧新趋势混合，二季度均更换了3只重仓股，其中三一重工、三花智控、温氏股份新进中欧新蓝筹混合的前十大重仓股，温氏股份、三花智控、中远海能新进中欧新趋势混合的前十大重仓股。药明生物回到中欧医疗创新的前十大重仓股中欧基金葛兰目前管理的公募产品有3只，最新披露的二季报显示，中欧医疗健康混合的规模约为328亿元，相比于一季度末的369亿元，有所下降。而在持仓方面，该基金二季度并没有对前十大重仓股作出明显调整，更多的是持股数的增减。比如减持了一部分的恒瑞医药、爱尔眼科、片仔癀等，同时，东阿阿胶、泰格医药等个股的持股数有比较明显的增加。相比于中欧医疗健康混合，中欧医疗创新的前十大重仓股有所调整，其中比较明显的变化是药明生物又回到前十大重仓股中，而一直以来重仓的爱尔眼科退出了前十大重仓股。葛兰在二季报中表示：“在经历了行业秩序规范化、内外部宏观因素考验的洗礼之后，只有具备核心产品竞争力、高效经营管理能力的优质企业才能够真正走出产业调整周期，迎来可持续的长期发展，这也是我们重点关注配置的方向。基于企业长期价值的投资思路，我们继续在创新药械及其产业链、消费医疗、OTC等方面进行了重点配置。”展望2024年三季度，葛兰认为：“在严肃医疗领域，医疗合规化仍在各个层面持续推进，我们预计医院端和企业端已经逐步适应了更加规范有序的新环境，医院诊疗、企业经营活动都在持续地向好恢复。考虑到2023年下半年仍处于行业合规化的适应调整期，企业经营端基数较低，2024年下半年有望实现一定程度的回升。”此外，葛兰还谈及创新药及《生物安全法案》的影响，葛兰表示：“创新药产业链方面，海外投融资持续回暖，有望拉动创新活动逐步活跃。对以海外市场为主的创新服务企业而言，《生物安全法案》预计仍会对业务产生一定扰动。国内投融资环境目前仍在逐步筑底阶段，但我们也看到部分企业的新签项目数同比仍呈现增长的趋势，新签订单金额在2024年下半年也有望逐步好转。”周蔚文：减持贵州茅台，重仓买入温氏股份再看中欧基金另一位基金经理周蔚文的调仓动作。截至二季度末，周蔚文的管理规模超过300亿元，其中管理时间最长的是中欧新蓝筹混合和中欧新趋势混合，均超过了12年。在重仓股方面，中欧新蓝筹混合的前十大重仓股更换了3只，三一重工、三花智控、温氏股份新进前十大，贵州茅台、巨星农牧、通策医疗退出前十大。二季报显示，中欧新趋势混合的前十大重仓股也更换了3只，温氏股份、三花智控、中远海能新进前十大。退出前十大的是春秋航空、贵州茅台和巨星农牧。周蔚文在二季报中对持仓结构的调整阐述了自己的观点，他表示：“基金基本维持年初组合，相对市场超配养殖和基础化工行业，我们看好其中有长期价值但短期业绩趋势受挫于行业景气度的优秀公司，相信这些公司的盈利在2024年甚至2025年都有望明显好转。这类公司中也包含了出口份额还可持续提高的、明显有全球竞争力的制造业，我们在二季度也进行了增配。”“同时，我们也看好新兴行业中部分能持续成长的优秀公司，考虑到落地路径和市场需求的清晰性，我们在人工智能的应用领域，增配了机器人和智能驾驶相关股票，减配了消费需求尚不明确的传媒。此外，对于消费主体不积极、量价均受到考验的食品饮料板块也进行了一定减持。”周蔚文进一步表示。封面图片来源：视觉中国-VCG41172727517","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2452123497"}